Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 8/20 | 0.36 |
| ▸ | HTR2C | P28335 | 8/20 | 0.36 |
| ▸ | HTR2B | P41595 | 8/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627327 | 1.00 | TRPA1 (0.42) | TRPA1HTR2AHTR2CHTR2BTRPM8 | |
| SCHEMBL4478989 | 1.00 | TRPA1 (0.42) | TRPA1HTR2AHTR2CHTR2BTRPM8 | |
| SCHEMBL13627313 | 0.86 | TRPA1 (0.36) | TRPA1HTR2AHTR2CHTR2BTRPM8 | |
| SCHEMBL4477342 | 0.86 | TRPA1 (0.36) | TRPA1HTR2AHTR2CHTR2BTRPM8 | |
| SCHEMBL4472523 | 0.86 | TRPA1 (0.36) | TRPA1HTR2AHTR2CHTR2BTRPM8 | |
| SCHEMBL4483043 | 0.80 | HTR2C (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL13627326 | 0.80 | HTR2C (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL13627348 | 0.80 | TRPA1 (0.41) | TRPA1HTR2AHTR2CHTR2BTRPM8 | |
| SCHEMBL4477738 | 0.80 | TRPA1 (0.41) | TRPA1HTR2AHTR2CHTR2BTRPM8 | |
| SCHEMBL13627329 | 0.74 | HTR2C (0.42) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618980-B2 | Pyrrolo(oxo)quinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-17 | — | — | US | claimed |
| US-20060014778-A1 | (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | claimed |
| US-7618980-B2 | Pyrrolo(oxo)quinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014778-A1 | (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, | HTR3B, HTR2C, HTR2B | TRPA1 655/4885HTR2A 8/4885HTR2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.